scPharmaceuticals (SCPH) Competitors

Praxis Precision Medicines (NASDAQ:PRAX) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.

Is PRAX or SCPH more profitable?

scPharmaceuticals has a net margin of -264.60% compared to Praxis Precision Medicines' net margin of -9,409.22%. Praxis Precision Medicines' return on equity of -54.86% beat scPharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	-9,409.22%	-54.86%	-50.52%
scPharmaceuticals	-264.60%	-244.93%	-68.56%

Do insiders & institutionals have more ownership in PRAX or SCPH?

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more risk and volatility, PRAX or SCPH?

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Does the MarketBeat Community favor PRAX or SCPH?

scPharmaceuticals received 112 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 74.24% of users gave Praxis Precision Medicines an outperform vote while only 66.80% of users gave scPharmaceuticals an outperform vote.

Company	Underperform	Outperform
Praxis Precision Medicines	Outperform Votes 49 74.24%	Underperform Votes 17 25.76%
scPharmaceuticals	Outperform Votes 161 66.80%	Underperform Votes 80 33.20%

Which has higher earnings and valuation, PRAX or SCPH?

scPharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	90.76	-$123.28M	-$10.27	-3.75
scPharmaceuticals	$30.28M	4.84	-$54.81M	-$1.90	-1.54

Does the media favor PRAX or SCPH?

In the previous week, Praxis Precision Medicines had 12 more articles in the media than scPharmaceuticals. MarketBeat recorded 29 mentions for Praxis Precision Medicines and 17 mentions for scPharmaceuticals. scPharmaceuticals' average media sentiment score of 0.39 beat Praxis Precision Medicines' score of -0.41 indicating that scPharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	15 Negative mention(s)	0 Very Negative mention(s)	Neutral
scPharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate PRAX or SCPH?

Praxis Precision Medicines currently has a consensus price target of $123.80, suggesting a potential upside of 221.56%. scPharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 411.95%. Given scPharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe scPharmaceuticals is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

scPharmaceuticals beats Praxis Precision Medicines on 11 of the 18 factors compared between the two stocks.